Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) MYBL2 Antibodies:
anti-Mouse (Murine) MYBL2 Antibodies:
anti-Human MYBL2 Antibodies:
Go to our pre-filtered search.
Rat (Rattus) Polyclonal MYBL2 Primary Antibody for ELISA, WB - ABIN251665
Shepard, Amatruda, Stern, Subramanian, Finkelstein, Ziai, Finley, Pfaff, Hersey, Zhou, Barut, Freedman, Lee, Spitsbergen, Neuberg, Weber, Golub, Glickman, Kutok, Aster, Zon: A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. in Proceedings of the National Academy of Sciences of the United States of America 2005
Cow (Bovine) Polyclonal MYBL2 Primary Antibody for IHC, WB - ABIN2792568
Tashiro, Sumi, Uozumi, Shimizu, Nakamura: B-Myb-dependent regulation of c-Myc expression by cytosolic phospholipase A2. in The Journal of biological chemistry 2004
Human Polyclonal MYBL2 Primary Antibody for ICC, IHC (p) - ABIN3044010
Tao, Wang, Xu, Li, Li, Xu, Fang, Li, Qian, Li, Li, Wu, Ren, Du, Lu, Feng, Wang, He, Hu, Pan: Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells. in Cancer cell international 2017
loss-of-function mutation (crb) in bmyb causes defects in mitotic progression and spindle formation and genome instability in embryos, and cancer susceptibility in adult crb heterozygotes
Downregulation of B-myb induced senescence by upregulation of p22(phox (show CYBA Antibodies)) and activation of the ROS (show ROS1 Antibodies)/p53 (show TP53 Antibodies)/p21 (show D4S234E Antibodies) pathway
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development.
MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia.
Results coupled with functional studies demonstrate that B-MYB not only controls and accelerates cell cycle progression in ESCs (show NR2E3 Antibodies) it contributes to fate decisions and maintenance of pluripotent stem cell identity.
Our data suggest that B-Myb is required as a pioneer factor to enable FoxM1 (show FOXM1 Antibodies) binding to G2/M gene promoters and explains how these transcription factors may collaborate to induce mitosis.
Mybl2 upregulation induces fast growth and progression of premalignant and malignant liver, through cell cycle deregulation and activation of genes and pathways related to tumor progression.
The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT.
Results describe the characterization of a corepressor site (downstream repression site (DRS (show SRPX Antibodies))) required for transcriptional regulation of the B-myb (MybL2 gene) promoter.
B-Myb repressor function is regulated by cyclin A phosph (show CCNA2 Antibodies)orylation and sequences within the C-terminal domain.
B-Myb has a role in regulation of c-Myc (show MYC Antibodies) expression by cytosolic phospholipase A2 (show PLA2G4A Antibodies)
results suggest that B-Myb-A3B (show SGCB Antibodies) contributes to DNA damage and could be targeted by inhibiting EGF receptor (show EGFR Antibodies).
The structure and biochemical analysis provide an understanding of how oncogenic B-Myb is recruited to regulate genes required for cell-cycle progression, and the MMB interface presents a potential therapeutic target to inhibit cancer cell proliferation.
B-Myb is an independent prognostic marker and serves as a potential target in the diagnosis and/or treatment of NSCLC, and that B-Myb functions as a tumor-promoting gene by targeting IGFBP3 (show IGFBP3 Antibodies) in NSCLC cells.
MYBL2 is a key downstream factor of Akt (show AKT1 Antibodies)/FoxM1 (show FOXM1 Antibodies) signaling to promote progression of human glioma, and could be a new candidate gene for molecular targeting therapy and biomarker for radiotherapy of glioma.
These results suggested that overexpression of MYBL2 might serve as a novel prognostic biomarker in pancreatic ductal adenocarcinoma patients
A total of 41 differentially expressed genes, such as SOCS3 (show SOCS3 Antibodies), VAPA (show VAPA Antibodies), and COL5A2 (show COL5A2 Antibodies), are speculated to have roles in the pathogenesis of acute myocardial infarction; 2 transcription factors FOXO3 (show FOXO3 Antibodies) and MYBL2, and 2 miRNAs hsa (show CD24 Antibodies)-miR (show MLXIP Antibodies)-21-5p and hsa (show CD24 Antibodies)-miR (show MLXIP Antibodies)-30c-5p may be involved in the regulation of the expression of these differentially expressed genes.
Results suggested that the oncogenic transcription factor HIF-2alpha (show EPAS1 Antibodies) stabilized VHL (show VHL Antibodies) disease suppressor B-Myb, which is also a transcription factor, by physical interaction. Some B-Myb-dependent gene expression was similarly affected by B-Myb or HIF-2alpha (show EPAS1 Antibodies) knockdown, suggesting that stabilization of B-Myb by HIF-2alpha (show EPAS1 Antibodies) may play a role in specific gene expressions.
The MuvB multiprotein complex, together with B-MYB and FOXM1 (show FOXM1 Antibodies) (MMB-FOXM1 (show FOXM1 Antibodies)) regulate the expression of mitotic kinesins in breast cancer cells.
MYBL2 overexpression promotes Gallbladder Cancer cell proliferation through the regulation of the cell cycle at the S and G2/M phase transitions. Thus, MYBL2 could serve as a potential prognostic and therapeutic biomarker in Gallbladder Cancer patients.
Study identified B-Myb as a substrate of the pVHL (show VHL Antibodies) ubiquitin ligase complex, which targets it for degradation via the ubiquitin-proteasome pathway. It also, provide evidence that the regulation of B-Myb by pVHL (show VHL Antibodies) plays a critical role in von Hippel-Lindau disease.
B-Myb (MYBL2)repressor function is regulated by cyclin A (show CCNA2 Antibodies) phosphorylation and sequences within the C-terminal domain.
B-Myb represses SMC (show DYM Antibodies) elastin (show ELN Antibodies) gene expression and cyclin A (show CCNA2 Antibodies) plays a role in the developmental regulation of elastin (show ELN Antibodies) gene expression in the aorta
The protein encoded by this gene, a member of the MYB family of transcription factor genes, is a nuclear protein involved in cell cycle progression. The encoded protein is phosphorylated by cyclin A/cyclin-dependent kinase 2 during the S-phase of the cell cycle and possesses both activator and repressor activities. It has been shown to activate the cell division cycle 2, cyclin D1, and insulin-like growth factor-binding protein 5 genes. Transcript variants may exist for this gene, but their full-length natures have not been determined.
v-myb myeloblastosis viral oncogene homolog (avian)-like 2
, myb-related protein B
, v-myb myeloblastosis viral oncogene homolog-like 2
, myb-like protein 2
, myb-related protein 1
, myeloblastosis oncogene-like 2